Erythropoietin in Acute Kidney Injury (EAKI): a pragmatic randomized clinical trial

Link to article at PubMed

BMC Nephrol. 2022 Mar 13;23(1):100. doi: 10.1186/s12882-022-02727-5.


BACKGROUND: Treatment with erythropoietin is well established for anemia in chronic kidney disease patients but not well studied in acute kidney injury.

METHODS: This is a multicenter, randomized, pragmatic controlled clinical trial. It included 134 hospitalized patients with anemia defined as hemoglobin < 11 g/dL and acute kidney injury defined as an increase of serum creatinine of ≥ 0.3 mg/dL within 48 h or 1.5 times baseline. One arm received recombinant human erythropoietin 4000 UI subcutaneously every other day (intervention; n = 67) and the second received standard of care (control; n = 67) during the hospitalization until discharge or death. The primary outcome was the need for transfusion; secondary outcomes were death, renal recovery, need for dialysis.

RESULTS: There was no statistically significant difference in transfusion need (RR = 1.05, 95%CI 0.65,1.68; p = 0.855), in renal recovery full or partial (RR = 0.96, 95%CI 0.81,1.15; p = 0.671), in need for dialysis (RR = 11.00, 95%CI 0.62, 195.08; p = 0.102) or in death (RR = 1.43, 95%CI 0.58,3.53; p = 0.440) between the erythropoietin and the control group.

CONCLUSIONS: Erythropoietin treatment had no impact on transfusions, renal recovery or mortality in acute kidney injury patients with anemia. The trial was registered on (NCT03401710, 17/01/2018).

PMID:35279078 | DOI:10.1186/s12882-022-02727-5

Leave a Reply

Your email address will not be published.